CIK 0001213037 · Non-accelerated filer<br>Smaller reporting company
Cardiff Oncology, Inc.
Sign in to watch- Ticker
- CRDF
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 272004382
- Phone
- 858-952-7570
- Business address
- 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
- Former names
- Trovagene, Inc., TrovaGene Inc., XENOMICS INC, USED KAR PARTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-26 | TANNENBAUM RENEE P Director | Grant or award · Stock Options | +40,565 | 168,766 | ||
| 2025-06-26 | Markin Rodney S Director | Grant or award · Stock Options | +40,565 | 222,865 | ||
| 2025-06-26 | Mohindru Mani Director | Grant or award · Stock Options | +40,565 | 168,766 | ||
| 2025-06-26 | Armitage James O Director | Grant or award · Stock Options | +40,565 | 187,539 | ||
| 2025-06-26 | White Lale Director | Grant or award · Stock Options | +40,565 | 158,681 | ||
| 2025-06-26 | PACE GARY W Director | Grant or award · Stock Options | +40,565 | 187,539 | ||
| 2025-03-11 | Kabbinavar Fairooz Chief Medical Officer | Grant or award · Stock Options | +150,000 | 780,008 | ||
| 2025-03-11 | Levine James E. Chief Financial Officer | Grant or award · Stock Options | +332,621 | 1,295,117 | ||
| 2025-03-11 | Smeal Tod Chief Scientific Officer | Grant or award · Stock Options | +332,621 | 979,805 | ||
| 2025-03-11 | Erlander Mark Chief Executive Officer | Grant or award · Stock Options | +758,400 | 2,925,098 | ||
| 2024-12-18 | Levine James E. Chief Financial Officer | Purchase | +2,400 | $5.00 | $12K | 67,716 |
| 2024-12-17 | Levine James E. Chief Financial Officer | Purchase | +2,752 | $5.42 | $15K | 65,316 |
| 2024-12-16 | Levine James E. Chief Financial Officer | Purchase | +2,564 | $3.83 | $10K | 62,564 |
| 2024-12-12 | TANNENBAUM RENEE P Director | Purchase | +10,000 | $3.42 | $34K | 20,000 |
| 2024-12-11 | PACE GARY W Director | Purchase | +350,115 | $2.60 | $910K | 1,047,876 |
| 2024-12-11 | PACE GARY W Director | Purchase | +11,500 | $2.60 | $30K | 1,059,376 |
| 2024-06-27 | White Lale Director | Grant or award · Stock Options | +29,700 | 146,974 | ||
| 2024-06-27 | TANNENBAUM RENEE P Director | Grant or award · Stock Options | +29,700 | 128,201 | ||
| 2024-06-27 | Mohindru Mani Director | Grant or award · Stock Options | +29,700 | 128,201 | ||
| 2024-06-27 | PACE GARY W Director | Grant or award · Stock Options | +29,700 | 146,974 |
Page 2 of 8 · 144 trades